2021欧洲预防指南与他汀初级预防资格比较
本研究基于哥本哈根普通人群研究66 909名40-69岁无ASCVD等疾病个体,比较2021欧洲ESC、美国ACC/AHA、英国NICE和2019 ESC/EAS指南的他汀一级预防资格。结果显示2021欧洲ESC指南仅4%符合他汀条件,敏感性12%,远低于其他指南;降低治疗阈值可改善性能。
要点
- 2021欧洲ESC指南下仅4%符合他汀一级预防,敏感性12%。
- 美国ACC/AHA指南34%符合,敏感性60%;英国NICE 26%符合,敏感性51%。
- 欧洲SCORE2校准优于其他模型,但阈值过高限制了他汀资格。
核心结论
- 2021欧洲ESC指南的新治疗阈值大幅降低低风险欧洲国家他汀一级预防资格,降低阈值可改善指南整体性能。
研究设计与样本
- 基于人群的当代队列研究,纳入哥本哈根普通人群研究66 909名40-69岁无ASCVD、糖尿病、慢性肾病且未使用他汀的个体,平均随访9.2年。
主要发现
- 随访期间,根据2021欧洲SCORE2、美国PCE和英国QRISK3模型定义,观察到2962至4277例非致死性和致死性ASCVD事件;根据2019欧洲SCORE1模型定义,观察到180例致死性ASCVD事件。
- 欧洲SCORE2的预测/观察ASCVD事件比为0.8,美国PCE为1.3,英国QRISK3为1.3,欧洲SCORE1为5.8。
- 对于40-69岁个体的一级预防I类推荐,2021欧洲ESC指南下2862/66 909(4%)符合他汀条件,美国ACC/AHA为23 029(34%),英国NICE为17 659(26%),2019欧洲ESC/EAS为13 496(20%)。
- 相应的检测未来欧洲SCORE2定义ASCVD事件的敏感性分别为12%、60%、51%和36%。
- 通过降低治疗阈值,欧洲ESC指南的敏感性可显著改善,而特异性损失较小;为达到与其他指南相似的临床性能,欧洲SCORE2阈值应总体降至5%以匹配美国ACC/AHA,降至6%以匹配英国NICE,降至7%以匹配2019欧洲ESC/EAS指南。
关键数值与推荐
- 2021欧洲ESC指南推荐:40-49岁10年ASCVD风险≥7.5%和50-69岁≥10%时启动他汀一级预防。
临床怎么用
- 在低风险欧洲国家,按2021欧洲ESC指南严格阈值可能导致他汀一级预防覆盖不足,考虑降低阈值可提高敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For primary prevention of atherosclerotic cardiovascular disease (ASCVD), the 2021 European Society of Cardiology (ESC) guidelines on statin use (hereafter European-ESC) recommend a new risk model (Systematic Coronary Risk Evaluation 2 [European-SCORE2]) as well as new age-specific treatment thresholds (≥7.5% 10-year ASCVD risk if aged 40-49 years and ≥10% if aged 50-69 years). OBJECTIVE: To compare the clinical performance of the 2021 European-ESC, American College of Cardiology/American Heart Association (hereafter US-ACC/AHA), UK National Institute for Health and Care Excellence (UK-NICE), and 2019 ESC/European Atherosclerosis Society (EAS) guidelines in apparently healthy individuals. DESIGN, SETTING, AND PARTICIPANTS: This population-based contemporary cohort study included 66 909 individuals from the Copenhagen General Population Study. Participants were aged 40 to 69 years and were free of ASCVD, diabetes, chronic kidney disease, and statin use at baseline in 2003 to 2015. Mean follow-up time was 9.2 years. Data were analyzed from November 2021 to April 2022. EXPOSURES: Statin treatment according to guideline criteria. MAIN OUTCOMES AND MEASURES: Calibration of risk calculators, statin eligibility, sensitivity, and specificity for ASCVD events according to guideline criteria. RESULTS: During follow-up, a range of 2962 to 4277 nonfatal and fatal ASCVD events was observed, as defined by the 2021 European-SCORE2, US pooled cohort equations (PCE), and UK-QRISK3 models, and 180 fatal ASCVD events were noted as defined by the 2019 European-SCORE1 model. European-SCORE2 was slightly better calibrated with a predicted/observed ASCVD event ratio of 0.8 vs 1.3 for US-PCE, 1.3 for UK-QRISK3, and 5.8 for European-SCORE1. For primary prevention class I recommendations in individuals aged 40 to 69 years, 2862 of 66 909 (4%) qualified for statins according to the 2021 European-ESC guidelines compared with 23 029 (34%) with US-ACC/AHA, 17 659 (26%) with UK-NICE, and 13 496 (20%) with 2019 European-ESC/EAS guidelines, with associated sensitivities for detecting future European-SCORE2-defined ASCVD events of 12%, 60%, 51%, and 36%, respectively. The sensitivity of the European-ESC guidelines was improved considerably by lowering the treatment thresholds, resulting in smaller losses in specificity. To obtain similar clinical performance with the 2021 European-ESC guidelines as in the other guidelines, the threshold with European-SCORE2 should be reduced to 5% overall to match US-ACC/AHA, to 6% to match UK-NICE, and to 7% to match 2019 European-ESC/EAS guidelines. CONCLUSIONS AND RELEVANCE: Despite an improved European-SCORE2 prediction model, the new treatment thresholds in the 2021 European-ESC guidelines dramatically reduce eligibility for primary prevention with statins in low-risk European countries. Using lower treatment thresholds can improve overall guideline performance.
引用
- Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG, et al. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines. JAMA Cardiol. 2022. PMID: 35793078. doi:10.1001/jamacardio.2022.1876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。